PipelineReview.com1d
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME ...
PipelineReview.com2d
Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative
At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing Derived from Novadip’s 3M 3 stem cell ...
PipelineReview.com2d
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
SOUTH SAN FRANCISCO, CA, USA I October 17, 2024 I Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative ...
PipelineReview.com2d
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)
-ATX-01 is the industry’s first anti-microRNA therapeutic to be investigated in DM1 – VALENCIA, Spain I October 18, 2024 I ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on ...
PipelineReview.com2d
Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. (“Baiyu”) today announced that it has entered into an exclusive license agreement with Novartis for a small molecule ...
PipelineReview.com3d
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026 SAN DIEGO, CA, USA I October 17, 2024 I Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage ...
PipelineReview.com3d
U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson’s Disease
NORTH CHICAGO, IL, USA I October 17, 2024 I AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and ...
PipelineReview.com3d
Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 for Infections Associated With Cystic Fibrosis
Following successful Phase 1b completion, Clarametyx is initiating the Phase 2a portion to assess CMTX-101 as an adjunct to standard of care for chronic infections COLUMBUS, OH, USA I October 17, 2024 ...